Pestalozzi advised private equity firm Susquehanna Private Capital on its investment in Spherix Global Insights, a pharmaceutical market insights firm. Pestalozzi advised Susquehanna with respect to all Swiss legal and tax aspects of this transaction.
Tags :Pestalozzi
Pestalozzi has appointed Lara Dorigo to its partnership. The firm also promoted Christophe Berclaz and Louis de Mestral to counsel. In addition, Kern Alexander is joining Pestalozzi as counsel. The appointments take effect on 1 January 2022.
Pestalozzi advises Pactiv Evergreen Inc., a Nasdaq listed company and specialists in the packaging and filling industry, in the sale by one of its carton packaging and filling machinery subsidiaries in China, Korea and Taiwan
Concentra Analytics, a London headquartered analytics technology firm and creators of orgvue, an enterprise organisational design and planning platform, has completed the acquisition of Dynaplan, a Swiss-Norwegian software and services provider of strategic workforce planning.
DNM Swiss received the decision from the Swiss Financial Market Supervisory Authority FINMA regarding its authorisation as trustee under the Financial Institutions Act. As of December 09, 2021, FINMA has granted only a very few trustee licenses
Lindab expands its current operations in Switzerland with the acquisition of Tecnovent. With the acquisition, Lindab will get access to sales and production of ventilation grilles, roof hoods and rectangular ventilation ducts. Tecnovent has a
Banco Comercial Português (“BCP”) entered into a share purchase and sale agreement with Union Bancaire Privee (“UBP”), pursuant to which UBP agreed to purchase all the shares in Banque Privee BCP (SUISSE). Following receipt
Stellantis has entered into an agreement to sell FCA Switzerland to Bergé Auto. The latter will be taking over responsibility for importing the Abarth, Fiat, Alfa Romeo, Jeep and Fiat Professional brands into Switzerland. The
Ten23 health, a pure-play, patient-centric and sustainable biologics drug product contract development and manufacturing organisation (“CDMO”), backed by 3i Group, has acquired all shares in swissfillon, an FDA and Swissmedic approved drug product-focused CDMO active
Helix Acquisition Corp, a Nasdaq-listed special purpose acquisition company and MoonLake Immunotherapeutics, a Swiss based clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases agreed on a business combination. At
